March 21, 2019

MIPS unable to replicate new WaveCel helmet technology performance claims

STOCKHOLM, SWEDEN — MARCH 21, 2019 As the leader in the field of rotational motion solutions for helmets, MIPS subjected the new WaveCel helmet technology to...
Read more
March 21, 2019

Orexo publishes the Annual Report for 2018

Uppsala, Sweden - March 21, 2019 – Orexo’s Annual Report, including the Sustainability Report, for the 2018 fiscal year has been published and can be downloaded on the com...
Read more
March 21, 2019

MIPS comments communication from Bontrager regarding new technology in some of its helmet models

March 21, 2019Non-regulatory Due to the significant interest among investors and the impact on MIPS’ share price as a result of information in media about bike gear comp...
Read more
March 20, 2019

Pfizer secures exclusive option to acquire gene therapy company Vivet Therapeutics

Pfizer and Vivet to collaborate on development of potential breakthrough therapy for Wilson disease Pfizer acquires 15% ownership stake in Vivet Paris, France and New York, U...
Read more
March 19, 2019

Altimmune Announces Positive Results from NasoVAX Extension Study

Seroprotective HAI antibody response persisted more than one year after vaccination Company seeking partnership for further development and commercialization of NasoVAX GAITHERSB...
Read more
March 14, 2019

Targovax grants Zelluna Immunotherapy an FTO license to intellectual property relating to mutant RAS T cell receptor technology

Thursday, March 14, 2019 Targovax grants Zelluna an FTO license to Targovax patents and know-how to further enable development of Zelluna’s mutant RAS T-cell receptor th...
Read more
March 13, 2019

BONESUPPORT™ launching a new product – BONIFY™ – US product portfolio expansion

Lund, Sweden, 08.00 CET, March 13, 2019 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids, today announced the launch of BONIFY™, a...
Read more
March 11, 2019

Strongbridge Biopharma plc Announces Top-Line Results from Extended Evaluation Phase of the Pivotal Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Potential Treatment of Endogenous Cushing’s Syndrome

~ Extended Evaluation Phase Meets Objective of Showing Positive Long-Term Benefit-Risk Profile of RECORLEV™ (levoketoconazole) ~ ~ Favorable Liver-Related Findings: No Patients ...
Read more
March 11, 2019

Modus Therapeutics strengthens management team with appointment of Mats Blom, MBA as CFO

STOCKHOLM, SWEDEN – 11 March 2019: Modus Therapeutics AB, a company developing innovative treatments for patients with high unmet medical needs and a focus on sickle cell disease...
Read more
March 4, 2019

Strongbridge Biopharma plc Announces Upcoming Presentation of New Data from Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome at the 2019 Annual Meeting of the Endocrine Society (ENDO)

DUBLIN, Ireland and TREVOSE, Pa., March 04, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company fo...
Read more
Older news →